Senti Biosciences Holdings (SNTI) Other Non-Current Assets (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Other Non-Current Assets of $3.5 million for Q4 2025, up 3260.0% year-over-year from $105000.0 in Q4 2024, and up 10276.47% quarter-over-quarter from $34000.0 in Q3 2025.
Senti Biosciences Holdings (SNTI) Other Non-Current Assets (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Other Non-Current Assets history runs 5 years deep, the most recent figure standing at $3.5 million for Q4 2025.
- In Q4 2025, Other Non-Current Assets rose 3260.0% year-over-year to $3.5 million; the TTM figure through Dec 2025 stood at $3.5 million (up 3260.0% YoY), while the FY2025 annual figure was $3.5 million, up 3260.0% from the prior year.
- Other Non-Current Assets for Q4 2025 stood at $3.5 million, up from $34000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $6.4 million in Q3 2023, with the low at $34000.0 in Q3 2025.
- The 5-year median for Other Non-Current Assets is $3.3 million (2021), against an average of $2.2 million.
- Peak annual rise in Other Non-Current Assets reached 3260.0% in 2025, while the deepest fall reached 99.05% in 2025.
- Senti Biosciences Holdings' Other Non-Current Assets stood at $3.3 million in 2021, then surged by 46.91% to $4.8 million in 2022, then slumped by 95.51% to $215000.0 in 2023, then slumped by 51.16% to $105000.0 in 2024, then surged by 3260.0% to $3.5 million in 2025.
- Business Quant data shows SNTI's Other Non-Current Assets at $3.5 million in Q4 2025, $34000.0 in Q3 2025, and $52000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - | 1.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.53 Mn |
| Sep 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 52,000.00 |
| Mar 31, 2025 | 76,000.00 |
| Dec 31, 2024 | 105,000.00 |
| Sep 30, 2024 | 3.56 Mn |
| Jun 30, 2024 | 76,000.00 |
| Mar 31, 2024 | 86,000.00 |
| Dec 31, 2023 | 215,000.00 |
| Sep 30, 2023 | 6.40 Mn |
| Jun 30, 2023 | 3.34 Mn |
| Mar 31, 2023 | 3.55 Mn |
| Dec 31, 2022 | 4.79 Mn |
| Sep 30, 2022 | 3.30 Mn |
| Jun 30, 2022 | 3.26 Mn |
| Mar 31, 2022 | 3.26 Mn |
| Dec 31, 2021 | 3.26 Mn |
| Sep 30, 2021 | 1.53 Mn |
| Jun 30, 2021 | 1.53 Mn |